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Abstract 
The typical cause of death in pulmonary hypertension (PH) is right ventricular (RV) 
failure, with females showing better survival rates than males. Recently, metabolic shift 
and mitochondrial dysfunction have been demonstrated in RV failure secondary to PH. 
In light of evidence showing that estrogen protects mitochondrial function and biogenesis 
in non-cardiovascular systems, we hypothesized that the mechanism by which estrogen 
preserves RV function is via protection of mitochondrial content and oxidative capacity in 
PH. We used a well-established model of PH (Sugen+Hypoxia) in ovariectomized female 
rats with/without estrogen treatment. RV functional measures were derived from 
pressure-volume relationships measured via RV catheterization in live rats. Citrate 
synthase activity, a marker of mitochondrial density, was measured in both RV and LV 
tissues. Respiratory capacity of mitochondria isolated from RV was measured using 
oxygraphy.  We found that RV ventricular-vascular coupling efficiency decreased in the 
placebo-treated SuHx rats (0.78±0.10 vs. 1.50±0.13 in control, P<0.05), whereas 
estrogen restored it. Mitochondrial density decreased in placebo-treated SuHx rats 
(0.12±0.01 vs. 0.15±0.01 U citrate synthase/mg in control, P<0.05), and estrogen 
attenuated the decrease. Mitochondrial quality and oxidative capacity tended to be lower 
in placebo-treated SuHx rats only. The changes in mitochondrial biogenesis and function 
paralleled the expression levels of PGC-1� in RV.  Our results suggest that estrogen 
protects RV function by preserving mitochondrial content and oxidative capacity. This 
provides a mechanism by which estrogen provides protection in female PH patients and 
paves the way to develop estrogen and its targets as a novel RV-specific therapy for PH.    
 
New & Noteworthy   
• Estrogen preserves the ventricular-vascular coupling efficiency in hypertrophied 
RV secondary to PH in rats by enhancing RV contractility with limited effects on 
RV afterload.  
• Estrogen prevents the decrease of mitochondrial density and oxidative capability 
















This article is protected by copyright. All rights reserved 
Keywords 






ATP   adenosine triphosphate 
BW  body weight 
CI   cardiac index 
CS  citrate synthase 
CO   cardiac output 
Ea
E
  effective arterial elastance 
es
EW  external work 
  end-systolic elastance 
LV   left ventricle  
LVS  left ventricle and septum  
OVX   ovariectomy 
PA   pulmonary artery  
P  end-systolic pressure  
PH   pulmonary hypertension 
PGC-1� Peroxisome proliferator-activated receptor gamma coactivator 1-� 
PP   pulse pressure 
PV  pressure-volume 
PVA  pressure-volume area 
RCR   respiratory control ratio 
RV   right ventricle  
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Introduction 
Pulmonary hypertension (PH) is a fast, progressive, fatal vascular disease of the lung, 
with a 3-year mortality rate of 55%(13). The major cause of death is right ventricular 
(RV) failure (29). Despite a higher incidence of PH in women than men, female PH 
patients have better RV function and a better survival rate than male patients (14, 16). 
Both clinical and animal studies have demonstrated that the female sex hormone 
estrogen prevents RV functional and structural deterioration in PH (8, 23, 46). Our recent 
study showed that estrogen has a direct inotropic effect on the RV in addition to reducing 
RV afterload (23). However, the underlying mechanisms by which estrogen protects the 
RV in PH remain unclear, which limits the therapeutic potential of estrogen-based RV-
specific therapies in PH.  
To function, the heart needs a continuous supply of chemical energy (or ATP), 95% of 
which comes from phosphorylation oxidation of the mitochondria (5). Akin to left ventricle 
failure secondary to systemic hypertension (40, 44), RV failure secondary to PH has 
been recently characterized by abnormal energy metabolism and mitochondrial 
dysfunction (9, 35). In adaption to increased afterload in PH, the RV exhibits abnormal 
mitochondrial oxidation by metabolically shifting from glucose oxidation to glycolysis (24, 
32), which is believed to underlie RV dysfunction because modulation of this metabolic 
shift improves RV function (34). Dysfunctional RVs in both humans and rats have 
demonstrated impaired mitochondria structure and respiration (9), consistent with a 
down-regulation of PGC-1� and its downstream target genes, which are involved in 
mitochondrial biogenesis and oxidative capacity (21, 47).  
Estrogen is well known to modulate mitochondrial biogenesis and function in brain and 
cancer cells (18), but few studies have investigated the effects of estrogen on 
mitochondria in the cardiovascular system. In rodent hearts with ischemia-reperfusion 
injury, estrogen-treated animals have higher mitochondrial complex IV expression (12), 
less mitochondrial damage, and greater maintenance of mitochondrial function (54) 
compared to the non-treated animals. The direct protective effects of estrogen on 
mitochondrial structure and function have been associated with improved cardiac 
function in these rodent hearts with ischemia-reperfusion injury (12, 54). However, it 
remains unknown whether the protection of RV function by estrogen is linked to its 
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Here, we hypothesized that estrogen preserves RV mitochondrial content and oxidative 
capacity, which protects the RV from dysfunction in severe PH. We used the 
sugen/hypoxia (SuHx) model of PH in rats (1), which recapitulates angio-obliterative 
features of human PH. Female rats were ovariectomized and some were supplemented 
with a physiological level of estrogen. We measured RV pressure-volume loops in vivo 
via RV catheterization, from which we derived RV function measures. In addition, we 
measured RV mitochondrial content and respiration of isolated RV mitochondria. We 
found that RV metabolic remodeling precedes RV systolic dysfunction and that the 
protective effect of estrogen on RV function is associated with preservation of 
mitochondrial density and function in PH. This study for the first time links the protection 
of estrogen on metabolic remodeling to RV functional adaption in PH and underscores 
the potential of estrogen as a RV-specific therapy. 
Methods 
Female Sprague-Dawley rats, 4 to 5 weeks old, were ovariectomized (OVX) by a 
commercial vendor (Harland Laboratory) to eliminate natural fluctuations in estrogen 
levels. After 1 week, to ensure depletion of endogenous estrogen stores, rats were 
implanted subcutaneously with either estradiol-17 pellets (75 �g/kg/day (19); Innovation 
Research of America) or placebo pellets as control for the effects of estrogen. 
Immediately following the pellet implantation to induce pulmonary hypertension, rats 
from both estrogen and placebo groups were injected intraperitoneally with the VEGF 
receptor inhibitor SU5416 at 20 mg/kg and exposed to normobaric hypoxia (10% O2) for 
4 weeks (SuHx), followed by 10 weeks of normoxia. Control rats from both estrogen and 
placebo groups received no SU5416 and were kept in room air conditions for 14 weeks. 
All rats were housed at room temperature with a 12-hour dark/light cycle and fed a 
copper-supplemented soy-free rodent diet (TD.130197, Harland) with free access to 
water. Of these animals, one group of rats (SuHx and control, estrogen and placebo 
treated, n=10-11 each) were used for echocardiography and RV pressure and volume 
measurements; terminal experiments were performed at the University of Wisconsin-
Madison. A second group of rats (SuHx and control, estrogen and placebo treated; n= 6 
each) were used for RV bioenergetic measurements; terminal experiments were 
performed at the University of Michigan. All procedures were approved by the University 
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of Wisconsin-Madison and University of Michigan Institutional Animal Care and Use 
Committees.  
Echocardiography: In the first group of rats, transthoracic echocardiography was 
performed to examine right ventricle (RV) morphology and function in vivo. As described 
previously (25), rats were ventilated with 1% isofluorane 99% O2 and maintained on a 
heated platform. RV wall thickness was obtained from M- mode images using the 
leading edge-to-leading edge convention (Visual Sonics Vevo 770 ultrasonography with 
a 17-MHz transducer). Pulmonary flow was measured at the level of the pulmonary 
valve using Doppler imaging. The isovolumic relaxation time and PA ejection time, the 
reference parameters for RV diastolic and systolic function, respectively, were derived 
from the pulmonary flow images as described (22). All parameters were measured over 
at least three consecutive cardiac cycles and averaged. Stroke volume (SV) was 
calculated as VTI × ��2/4, where VTI is the time integral of flow velocity, and D is the 
PA diameter at the site where the flow was measured, and obtained at diastole in B-
mode images. Cardiac output (CO) was calculated as SV × heart rate. Rats were 
allowed to recover before pressure and volume measurements were obtained via right 
heart catheterization.  
Hemodynamics 
Right Heart Catheterization: RV pressure and volume (PV) were measured 
simultaneously following the procedures described by Liu (23). Briefly, rats were 
anesthetized with urethane (2.0 mg/kg), intubated, and ventilated at room air with a tidal 
volume of 2-2.5 ml and a respiratory rate of 80-100 breaths/min to minimize the impact 
of open-chest surgery on the heart rate and respiration of the animal (43). The animal 
was placed supine on a heated pad to keep the body temperature at ~37∘C. After a 
tracheotomy was performed, a 1.9 F variable segment admittance PV catheter was 
inserted into the RV through the apex to acquire PV loops. Signals were recorded at 
1,000 Hz. After baseline recordings, a brief vena cava occlusion was performed to alter 
venous return. Systemic pressure was monitored at the aortic arch via the right carotid 
artery.  
RV function was quantified using well-established parameters derived from baseline RV 
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maximal and minimal derivative of pressure (dP/dtmax and dP/dtmin), and chamber 
compliance (SV/ RV PP). To account for hypertension and estrogen- dependent weight 
changes, cardiac index (CI) was calculated as CO normalized by body weight (BW). 
Load-independent indices of systolic function such as end-systolic elastance (Ees) were 
derived from PV loops with vena cava occlusion. To assess RV afterload and 
ventricular-vascular coupling efficiency, effective arterial elastance (Ea), and Ees/Ea 
were calculated (17, 41). Cardiac energetics were assessed via pressure-volume area 
(PVA; an estimation of myocardial oxygen consumption), external work, and ventricular 
mechanical efficiency derived from the baseline RV PV relations as previously 
established (31).  
Tissue preparation: After induction of anesthsia with intraperitoneal injection of ketamine 
(90 mg/kg) and dexmedetomidine (0.5 mg/kg) followed by 0.5 mL heparin (1000 USP 
units/mL), the heart was cannulated in situ to perfuse the heart with ice-cold cardioplegia 
solution (5 mM KCl, 100 mM NaCl, 10 mM Dextrose, 25 mM MOPS, 1 mM EGTA, pH 
7.2) for 5 min in order to remove residual blood. The RV and LV free walls, were then 
quickly disected, blotted, and weighed. Tissue samples were used for mitochondrial 
isolation (~150 mg) and mitochondrial content determination through citrate synthase 
activity assay (~10 mg). 
Bioenergetics 
Mitochondrial isolation: Because myocytes consists of 75% of heart volume (50), the 
majority of mitochondria isolated from heart tissues were from myocytes. The tissue 
samples for mitochondrial isolation were minced and homeogenized in ice-cold isolation 
buffer (200 mM mannitol, 50 mM sucrose, 5 mM KH2PO4, 5 mM MOPS, 1 mM EGTA, 
0.1% BSA, pH 7.2) containing protease solution (5 U/ml in 2.5 ml finally diluated to 25 
ml) with a hand-hold CAT X120 homogenizer. RV mitochondria were isolated using 
differential centrifugation as described previously (49). Briefly, the homogenate was 
twice centrifuged (Eppendorf F-34-6-38 rotor and 5810R centrifuge) under 4 °C at high 
speed i.e., 8000 rcf for 10 min to remove the protease. The supernatant was discarded 
and the pellets were re-suspended in isolation buffer and centrifuged at 700 rcf to 
remove other cellular debris. The supernatant was centrifuged again at 8000 rcf to yield 
mitochondrial pellets. The mitochondrial pellets were re-suspended in a small volume of 
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Citrate synthase activity: Citrate synthase (CS) activity, a marker of mitochondrial 
density, was measured in both RV and LV tissues, as well as in the mitochondrial 
suspension, polarographically in a spectrometer as previously described (7). Heart 
tissues were minced and homogenized in 0.1M Tris (pH7) with a hand-hold CAT x 120 
homogenizer for 20 seconds before CS activity measurement. A mitochondrial 
concentration equivalent to 0.337 units of CS activity/ml (which corresponds to ∼0.1 mg 
protein/ml in a Bradford assay calibrated against bovine serum albumin standards) was 
used in mitochondrial respiration.  
Oxygraphy: Oxygen consumption was measured at 37°C using high resolution Oroboros 
oxygraphy (Oxygraph 2K, Oroboros Instruments, Innsbruck, Austria), as described in 
(48). Briefly, respiration was measured in respiration buffer (107.5 mM KCl, 5 mM 
K2HPO4, 50 mM MOPS, 1 mM EGTA, 1.5mM MgCl2, and 0.1% w/w BSA essentially 
fatty acid free) pH to 7.2 at 37∘C. The amount of mitochondria used was determined by 
their CS activity (337 milli-units CS per ml of respiration buffer in the oxygraph chamber 
– 2ml total).   
The following respiratory parameters were measured in order: (1) Basal respiratory rate 
(V0), respiratory rate (Vsub) after addition of substrates (State 2 respiration); and maximal 
respiratory rate (Vmax) after addition of ADP 500 µM final (state 3 respiration). The 
functional integrity of the mitochondria was assessed by the respiratory control index 
defined here as Vmax/Vsub
The P/O ratio, the ratio of rate of ATP synthesis to rate of oxygen atom consumption, 
was determined for respiration using carbohydrate and fatty acid substrates. Briefly, 674 
milli-units CS equivalent of mitochondria suspension and substrates (2 mM malate and 
350 µM pyruvate, or 2 mM malate and 20 µM palmitoyl-L-carnitine) were sequentially 
added into 2 ml of respiration buffer as described above. After 2 minutes of incubation to 
establish an energized mitochondrial state 2, as solution of 250 µM ADP was infused 
into the oxygraphic media at a rate of 0.026 µl/s for 380 seconds. The P/O ratio was 
determined as the ratio between the rate of ADP infusion and the measured rate of 
oxygen atom consumed. 
(state 3/state 2 respiration).Two combinations of substrates 
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Protein immunoblotting: Right ventricular tissues were homogenized and lysed in RIPA 
buffer (25 mM Tris•HCl pH 7.6, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 
0.1% SDS) plus 1:100 HALT protease and phosphatase inhibitor cocktail (Thermo 
Scientific, Rockford, IL). Equal amounts of protein for each sample were separated by 
SDS-PAGE, transferred onto a nitrocellulose membrane, and immunoblotted. Anti-
PGC1-α primary antibody (Santa Cruz Biotechnology, Santa Cruz, CA) was used at a 
dilution of 1:500. Anti-Actin primary antibody (Santa Cruz Biotechnology, Santa Cruz, 
CA) was used as a loading control. Bands were visualized with ECL Western blotting 
substrate (Thermo Scientific, Rockford, IL). Band intensity was quantitated using NIH 
ImageJ software.  
All results are presented as mean ± standard error. The significance of the changes in 
RV function and bioenergetics with estrogen treatment and SuHx exposure was 
assessed with two-way analysis of variance (estrogen vs. placebo and SuHx vs. control) 
followed with Tukey multiple comparisons at a significance level of 0.05. Statistical 
analysis was performed using R software (Foundation for statistical computing, version 
2.5.1). 
Statistical analysis  
Results 
As estrogen significantly influenced the body size and weight of the animals (Table 1), 
normalized right ventricular remodeling indices (RV/BW, RV/LVS and RV/TL) were used 
to assess RV hypertrophy. All these measures significantly increased in the placebo-
treated SuHx group, indicative of RV hypertrophy in PH.  Estrogen treatment attenuated 
the increase in RV/LVS and RV/TL in the SuHx group. Consistent with this result, the RV 
wall thickness measured using echocardiography significantly increased in the placebo-
treated SuHx group, but not in the estrogen-treated SuHx group (Table 2).  
Estrogen attenuated RV structural remodeling in rats with PH 
SuHx significantly increased pulmonary P
Estrogen protected RV function and mechanical efficiency in rats with PH 
es in rats (Table 3), indicating successful 
creation of PH. Ea, an index for RV afterload, significantly increased in both placebo- 
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for load-independent ventricular contractility, did not increase with Ea in the placebo-
treated SuHx group, resulting in a significant reduction of ventricular-vascular coupling 
efficiency (Ees/Ea
The total mechanical energy generated by ventricular contraction represented by PVA 
significantly increased in both SuHx groups (Figure 2A). The effective energy output 
(EW) significantly increased in the estrogen-treated SuHx group but did not change in 
the placebo-treated SuHx group (Figure 2B). As a result, the cardiac mechanical 
efficiency (EW/PVA) decreased in the placebo-treated SuHx group, whereas mechanical 
efficiency was preserved in the estrogen-treated SuHx group (Figure 2C).  
). As estrogen treatment tended to improve RV contractility (although 
no statistical significance was detected), the ventricular-vascular coupling efficiency was 
maintained in the estrogen-treated SuHx group. While neither SV nor CO was affected 
by SuHx exposure or estrogen treatment, CI was higher in the estrogen-treated rats 
compared to the placebo-treated rats (Table 3). SV/RV PP, an index for ventricular 
compliance, decreased in both placebo- and estrogen-treated SuHx groups, indicative of 
stiffer RV in PH. The increase in ventricular stiffness is consistent with an increase in the 
isovolumic relaxation time, an echocardiographic measure of RV diastolic dysfunction 
(Table 2).  
The total CS activity of the entire RV was significantly higher in the placebo-treated 
SuHx group than in the control and estrogen-treated SuHx groups (Figure 3A), due 
primarily to the fact that the total mass of RV tissue was significantly elevated in this 
group compared to the others. However, CS activity measured per unit mass of RV 
tissue was significantly lower in the placebo-treated SuHx group, suggesting a decrease 
in mitochondrial density. Estrogen treatment attenuated the decrease in the normalized 
CS activity and thus acted to maintain the mitochondrial density in PH (Figure 3B). CS 
activity in LV did not change with either SuHx or estrogen treatment (Figure 3C). The 
RCR, a measure of mitochondrial coupling, and V
Estrogen protected RV metabolic remodeling in rats with PH 
max , a measure of mitochondrial 
respiration capacity, tended to be lower in both pyruvate and palmitoyl-L-carnitine as the 
substrate in the placebo-treated SuHx group compared to the control (Figure 4A-D). 
Estrogen treatment attenuated the decrease in RCR and Vmax, suggesting that estrogen 
protected against damage to the quality and respiration capability of RV mitochondria in 
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unit mass of RV, followed the same trend as the mitochondrial respiration capacity 
(Figure 4E and F). The P/O ratio, a measure of mitochondrial respiratory efficiency, was 
significantly higher in the substrate palmitoyl-L-carnitine in the placebo-treated SuHx 
group compared to the control group, and estrogen had limited effect on the P/O ratio in 
both substrates (Figure 5).  
PGC-1α is known to be a key regulator of oxidative metabolism and mitochondrial 
function and has recently been shown to be down-regulated in the setting of SuHx-
induced PH and RV failure (9). Given our findings of decreased mitochondrial density 
and oxidative capacity in the setting of PH, which was restored by estrogen treatment, 
we examined the effect of estrogen treatment on PGC-1α. As demonstrated by Figure 6, 
there is an over 40% decrease in PGC-1α expression in the RV in the setting of PH. 
Estrogen treatment led to a significant increase in PGC-1α expression under control 
conditions. Additionally, estrogen treatment led to the preservation of PGC-1α levels at 
near control levels with PH. Consistent with our findings of estrogen’s protective effects 
on mitochondrial density and oxidative capacity, this result indicates that increasing 
PGC-1α levels is one mechanism by which estrogen preserves RV metabolism and 
function in the setting of PH.  
Discussion 
In this study, we investigated the metabolic mechanisms behind the protection of 
estrogen on RV function in PH. We revealed for the first time that estrogen preserved 
RV ventricular-vascular efficiency by enhancing RV contractility reserve with limited 
effects on the afterload in a rat model of PH. We also demonstrated decreases in RV 
mitochondrial density and function with an increase in afterload that did not occur in the 
presence of estrogen. These results suggest that the protective effects of estrogen on 
RV function are linked to metabolism. We believe that our findings will contribute to an 
improved understanding of RV failure and more effective therapies to combat this 
devastating disease.  
To resolve sex disparities in PH outcomes, researchers have focused on the roles of the 
female sex hormone estrogen in RV adaptation and demonstrated that estrogen limits 
RV functional and structural remodeling (8, 27). For example, Frump and colleagues 
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hemodynamics and protected RV exercise capacity (8). Nadadur and colleagues (27) 
showed that estrogen therapy reversed RV remodeling and prevented RV progression to 
failure in rats treated with monocrotaline. While intriguing, these studies lack thorough 
mechanical measurements of RV function and the interaction between the RV and 
pulmonary vascular bed, which makes it difficult to evaluate whether estrogen improves 
RV performance through direct (i.e., enhancing myocardial contraction) or indirect (i.e., 
attenuating pulmonary vascular remodeling) means. Using PV loops from RV 
catheterization in live mice, we previously revealed that estrogen has a direct inotropic 
effect on the RV and also attenuates the increase in RV afterload in an early, mild stage 
of PH (23). However, as PH progresses, the mechanisms of estrogenic protection on the 
RV may evolve. In this study, using a well-established model of a late, severe stage of 
PH in rats, we revealed for the first time that estrogen enhanced RV contractility with 
limited effects on RV afterload, resulting in preserved ventricular-vascular coupling 
efficiency. Estrogen enhanced CI and Ees
It is also worth noting that the SuHx exposure in our study did not create the same level 
of severity as previously reported (8, 36, 45), which can be attributed to different 
SuHx/Normoxia protocols, different dosage of Sugen, and different strains or colonies of 
rats. It has been reported that SuHx-induced increase in RV systolic pressure regressed 
after the rats returned to normoxia (36). Variation in the strains of rats, even between 
colonies of the same strain has a remarkable influence on the response to SuHx (15). In 
this study, the prolonged exposure to normoxia and the rat colony likely explain the less 
severe phenotype of PH compared to the other studies. Despite the fact that the no 
animals exhibited overt RV failure (i.e., CO and EF were preserved in all animals), the 
decrease in ventricular-vascular coupling efficiency in the placebo-treated diseased 
animals suggests a transition of RV function from a compensated state to a de-
compensated state (51). 
 in both control and diseased animals 
compared to the placebo-treated animals, similar to the previous findings (8, 20), 
indicating that estrogen mediates superior adaption of RV function to PH. Interestingly 
this enhancement in RV function did not result in additional energy demands because 
estrogen preserved mechanical efficiency.  
Cardiac mitochondria are the powerhouse of the heart; and mitochondrial abnormalities 
play a pivotal role in the development of heart failure (2). In the hypertrophied and failing 
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increased reactive oxygen species (ROS) production (37), mitochondrial structural and 
functional abnormalities (9, 30), and a metabolic shift from fatty acid oxidation to 
glycolysis (35). Drugs targeting some of these mitochondrial derangements have been 
shown to improve RV function (26, 34, 38), which links RV metabolic remodeling and 
mechanical function in PH. In this study, we sought to reveal the mitochondrial basis of 
estrogenic protection on RV adaptation to the persistently increased afterload in PH. 
Similar to a previous study in male rats (9), we found that in estrogen deficient (OVX) 
female rats, mitochondrial volume density in RV but not in LV decreased while the total 
number of mitochondria in RV increased, indicating that the rate of mitochondria 
biogenesis could not keep pace with the rate of tissue growth in response to increased 
afterload. This decrease in mitochondria volume density was paralleled by the reduced 
expression of PGC-1�, the master regulator of mitochondrial biogenesis (42), suggesting 
that the decreased mitochondrial density was a result of the defects in the translational 
pathway in mitochondria biogenesis. Moreover, we found that estrogen repletion 
preserved RV PGC-1� and mitochondrial content. This finding is profound because 
animal studies on LV failure suggest that impaired mitochondrial biogenesis due to 
down-regulation of PGC-1� transcriptional pathway is integral to mitochondrial 
dysfunction (47). The preservation of mitochondrial biogenesis underlies the protective 
effects of estrogen on RV function and provides a mechanistic basis for estrogen as a 
novel RV-specific therapy in PH. The abilities of estrogen to preserve mitochondrial 
biogenesis and PGC-1� expression have been also documented in the trauma-
hemorrhage mouse heart model (10, 11). 
Besides reduced mitochondrial density, mitochondrial quality measured with RCR and 
ADP-stimulated oxidation capability tended to be depressed in the hypertrophied RV. 
The low RCR, a quality measure for mitochondrial preparation, in the placebo-treated 
SuHx rats implies that either the RV mitochondria in these animals were damaged or 
prone to be damaged even though the isolation procedures for all the animals were the 
same.  This finding is consistent with the observations of abnormalities in ultrastructure 
of RV mitochondria and ROS-induced mtDNA damage in the dysfunctional RV tissues in 
male rats with SuHx-induced severe PH (9). The reduction of mitochondrial oxygen 
consumption rate in RV myocytes was also reported in monocrotaline-induced RV 
dysfunction, and the reduction of mitochondrial oxidative capacity was inversely related 
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finding that estrogen attenuated the alterations in mitochondria quality and oxidation 
capacity further support the involvement of mitochondria in the estrogenic protection of 
RV function. In the PH-induced failing RV, failure is associated increased ROS 
production (37), which is known to cause mitochondrial structural and functional 
damage. The anti-oxidant properties of estrogen may protect myocardial mitochondria 
against oxidative damage (3, 33).  
Surprisingly, the P/O ratio, an index for respiration efficiency, increased in the substrate 
palmitoyl-L-carnitine in the placebo-treated SuHx rats, indicating lower oxygen 
consumption per unit of ADP provided in fatty acid oxidation and estrogen had limited 
effects on the P/O ratio. The P/O ratio in the substrate pyruvate followed a similar trend.  
The SuHx-induced increase in respiration efficiency is opposite to the finding by Drake 
and colleagues (6), who showed that P/O ratio was reduced in male SuHx rats. We 
speculate that the different findings in the P/O ratio are attributable to different stages of 
RV dysfunction and/or sex differences in mitochondrial accommodation to pressure-
overload (52). The increase in efficiency of oxygen consumption likely represents 
another compensatory mechanism besides the metabolic switch to meet the increasing 
energy demand.  
 
We used different cohorts of animals to conduct the mechanical and metabolism studies 
to preserve tissue quality for the latter. To minimize the differences between the two 
cohorts, we tightly controlled the animal colony, age, feed, and treatment to be the 
same. Also, RV mitochondria were isolated and therefore not tested in their in vivo 
environment, which is known to affect mitochondrial function and can be altered by RV 
remodeling (39, 53). Since all the preparation procedures for mitochondria were kept the 
same for all the experimental groups, we expect the trends would hold or be further 
amplified in their physiological conditions. Further, our SuHx protocol did not create PH 
as severe as prior reports and did not create RV failure; thus, the protection of estrogen 
on RV function and mitochondrial remodeling was not as pronounced as would be 
expected in the failing RV. However, our model captured indicators of a transition from a 
compensated RV to a de-compensated RV and suggests that mitochondrial remodeling 
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Conclusions 
Despite the significance of RV function to survival in PH, there are no therapies that 
directly and selectively improve RV function. Motivated by the clinical observation that 
female patients have superior RV functional adaption in PH, we investigated the 
metabolic mechanisms by which estrogen offers protection to RV function in PH. Our 
study for the first time reveals that estrogen preserves RV mitochondrial density and 
tends to preserve function in PH-induced RV hypertrophy, which may underlie the 
estrogenic improvement of RV contractility and mechanical efficiency. If derangements 
in mitochondria occur early and precede the transition from RV dysfunction to failure, 
estrogen could be the basis of a novel RV specific therapy for PH patients.  
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 Control_Placebo Control_Estrogen SuHx_Placebo SuHx_Estrogen 
BW, g 335.3±6.5 219.0±10.1# 326.2±5.8 212.2±9.7# 
RV, mg 172.4±4.5 148.9±6.2 284.7±22.4* 167.6±6.5# 
LVS, mg 684.5±16.0 544.5±23.7# 746.5±30.7 546.4±21.0# 
TL, mm 40.0±0.4 34.5±1.2# 39.9±0.3 35.8±0.6# 
RV/BW, 
mg/g 
0.52±0.01 0.67±0.02 0.87±0.07* 0.82±0.05 
LVS/BW, 
mg/g 
2.05±0.04 2.44±0.06# 2.29±0.09 2.63±0.09# 
RV/LVS, 
mg/mg 
0.252±0.004 0.28±0.01 0.38±0.02* 0.31±0.02# 
RV/TL, 
mg/mm 
4.3±0.1 4.2±0.2 7.1±0.5* 4.7±0.2# 
Data = mean± SE. BW, body weight; RV, right ventricle; LVS, left ventricle plus septum; 
TL, tibia bone length. *, P<0.05 vs. Control; #, P<0.05 vs. Placebo. n = 10-11 in all 
groups.  
 
Table 2. Morphological and hemodynamic parameters measured using 
echocardiography in live rats. 
 Control_Placebo Control_Estrogen SuHx_Placebo SuHx_Estrogen 
h, mm 0.62±0.06 0.61±0.05 0.86±0.04* 0.76±0.03 
SV, µl 214.7±9.8 184.8±12.8 208.0±10.1 176.2±12.2 
CO, ml/min  71.5±3.9 63.9±4.9 69.3±4.6 60.7±5.5 
CI, 
ml/min/kg  
213.6±10.4 311.0±23.7# 212.3±12.7 288.0±20.3 
IVRT, ms 29.4±1.2 24.1±1.6 34.7±1.7 29.7±1.7* 
ET, ms 77.2±2.9 68.2±2.4 67.6±1.5 54.8±4.9* 
Data = mean± SE. h, ventricular wall thickness; SV, stroke volume; CO, cardiac output; 
CI, cardiac index; IVRT, isovolumic relaxation time; ET, ejection time.  
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Table 3. Hemodynamic parameters measured using right heart catheterization in live 
rats. 
 Control_Placebo Control_Estrogen SuHx_Placebo SuHx_Estrogen 
sys Ps 112.8±6.9 ,  
mmHg  
110.4±6.0 132.6±5.1 119±6 
Pes 24.2±1.1 , mmHg 24.7±1.4 45.6±5.6* 40.6±3.7* 
dP/dt max 2719±168 , 
mmHg/s 
2385±219 4066±262* 3273±310 
dP/dt min -2064±137 ,  
mmHg/s 
-1857±196 −3426 ±290* -2664±460 
EF, % 56±3 63±3 54±3 52±5 
HR, bpm 350±10 329±18.7 341±13 338±17 
SV, µl 283.5±15.5 245.6±17.3 246.8±14.6 226.5±16.2 
CO, ml/min 98.7±4.9 80.5±7.0 83.2±3.8 76.2±6.1 
CI, 
ml/min/kg 
293.3±14.0 380.9±26.5# 252.4±8.6 360.9±22.8# 
SV/RV PP, 
µl/mmHg 
13.3±1.0 11.8±1.0 6.3±0.5* 6.4±0.7* 
Hct 49±1 , % 42±1# 48±1 41±2 
Data = mean± SE. sys Ps, peak systemic pressure; Pes, end-systolic pulmonary 
pressure; dP/dt max and dP/dt min
 
, maximal and minimal pressure gradient; HR, heart 
rate; SV, stroke volume; CO, cardiac output; CI, cardiac index; SV/RV PP, ventricular 






Figure 1. Estrogen protects right ventricular-vascular coupling in SuHx-induced PH. (A) 
Arterial elastance, Ea; (B) end-systolic elastance, Ees; and (C) ventricular-vascular 
coupling efficiency, Ees/Ea
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Figure 2. Estrogen protects RV mechanical efficiency in SuHx-induced PH. (A) pressure-
volume area, PVA; (B) External work, EW; and (C) mechanical efficiency, EW/PVA. *, 
P<0.05 vs. Control, #, P<0.05 vs. Placebo. n = 9-11 in all groups. 
 
Figure 3. Estrogen protects citrate RV synthase (CS) activity in SuHx induced PH. (A) 
RV CS activity normalized by RV weight; (B) CS activity of the entire RV; and (C) LV CS 
activity normalized by LV weight. *, P<0.05 vs. Control, #, P<0.05 vs. Placebo. n = 4-6 in 
all groups. 
 
Figure 4. Effects of estrogen on RV mitochondrial quality and oxidative capacity in SuHx-
induced PH. Respiratory control ratio, RCR in substrates pyruvate (A) and palmitoyl-L-
carnitine (B); Mitochondrial maximal oxygen consumption rate (Vmax
 
) of state 3 in 
substrates pyruvate (C) and palmitoyl-L-carnitine (D); RV tissue respiration capacity in 
substrates pyruvate (E) and palmitoyl-L-carnitine (F). n = 4-6 in all groups. 
Figure 5. RV mitochondrial P/O ratio measured in pyruvate (A) and palmitoyl-L-carnitine 
(B). *, P<0.05 vs. Control, #, P<0.05 vs. Placebo. n= 4-6 in all groups.  
 
Figure 6. Representative immunoblot (upper panel) showing PGC-1α expression for 
control and SuHx rat RV with placebo or estrogen treatment. Actin was used as a 
loading control. Densitometric analysis shown below. *, P<0.05 vs. Control, #, P<0.05 
vs. Placebo. n=5-6 in all groups.  
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